Trial reportIn vivo (Athens, Greece)
Immune-modulating Effect of Korean Red Ginseng by Balancing the Ratio of Peripheral T Lymphocytes in Bile Duct or Pancreatic Cancer Patients With Adjuvant Chemotherapy.
Trial report in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Nrf2 as a therapeutic target of ginseng: A comprehensive review from preclinical evidence to clinical applications.Journal of ginseng research · 2026Review
- Evaluating the Hepatoprotective Effect ofFood science & nutrition · 2026Article
- Research progress of ginseng active ingredients combined with chemotherapy in cancer therapy.Journal of ginseng research · 2026Review
- TF-343 Recovered Cyclophosphamide-Induced Compromised Immune Status in a Mouse Model.Journal of microbiology and biotechnology · 2025Article
- Long-term oncologic benefit of postoperative chemotherapy in the resected ampulla of Vater cancer: hope or hype? A propensity score matching analysis.Annals of surgical treatment and research · 2025Article
- Protective effects of Panax ginseng as a medical food against chemical toxic agents: molecular and cellular mechanisms.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Current status of Complementary and Alternative Medicine Interventions in the Management of Pancreatic Cancer - An Overview.Current treatment options in oncology · 2023Review
- Therapeutic Strategies for Pancreatic-Cancer-Related Type 2 Diabetes Centered around Natural Products.International journal of molecular sciences · 2023Review
- Protective role of ginseng in endometriosis during covid-19.Journal of ginseng research · 2023Review
- Saponins of ginseng products: a review of their transformation in processing.Frontiers in pharmacology · 2023Review
- Network Pharmacology of Ginseng (Part II): The Differential Effects of Red Ginseng and Ginsenoside Rg5 in Cancer and Heart Diseases as Determined by Transcriptomics.Pharmaceuticals (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimWe aimed to clarify the clinical effect of Korean Red ginseng administered with adjuvant chemotherapy on the immune function of patients with bile duct or pancreatic cancer. PATIENTS AND
methodsThis was a prospective, randomized controlled trial conducted at a single tertiary center. Twenty-six consecutive patients who underwent curative resection for bile duct or pancreatic cancer followed by 5-fluorouracil/leucovorin or gemcitabine chemotherapy were included. They were randomized 1:1 to the ginseng and control groups. Immune and inflammatory markers were assayed in peripheral blood samples during and after chemotherapy.
resultsIntergroup differences in immune-related parameters before and during chemotherapy were not significant. After chemotherapy, the percentage of CD4
conclusionThe ginseng group, which received Korean Red ginseng daily during adjuvant chemotherapy, showed higher levels of CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.